Is Through Sickness and Hell a Hit or Flop? Official Box Office Record & Profit Analysis

Detailed Financial Report

Through Sickness and Hell, released in 2025, entered the cinematic marketplace as a Drama / Thriller film. The production path for this project involved significant capital, with a reported budget of approximately $50.0M. In the modern film economy, recovering such an investment requires a multifaceted theatrical strategy spanning domestic and international territories.

Collection Trajectory

The box office journey for Through Sickness and Hell has culminated in a worldwide gross of approximately $30.0M. This figure represents the total theatrical footprint, reflecting a Return on Investment (ROI) of -40%. The collection trajectory points to a challenging market response, where the theatrical gross struggled to clear the traditional break-even multiplier required for production and marketing recovery.

Profitability & Verdict

Analyzing the multiplier effect and market sentiment, Through Sickness and Hell navigated the competitive landscape with an audience reception score of 0/10. When weighing the production costs against the global returns, Through Sickness and Hell is effectively categorized as a Disaster. It serves as an analytical benchmark for the complexities of modern theatrical distribution and evolving viewer preferences.

Comparables

In the context of other Drama releases, the performance of Through Sickness and Hell will likely influence how studios approach similar projects in the future. Whether through its innovative visual style or its narrative choices, the film's financial footprint remains a key piece of the 2025 box office narrative.